PubMed:25054392
Annnotations
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 229-251 | HP_0009830 | denotes | peripheral neuropathic |
| T2 | 252-256 | HP_0012531 | denotes | pain |
Allie
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| SS1_25054392_2_0 | 123-140 | expanded | denotes | prolonged release |
| SS2_25054392_2_0 | 142-144 | abbr | denotes | PR |
| SS1_25054392_4_0 | 364-382 | expanded | denotes | controlled release |
| SS2_25054392_4_0 | 384-386 | abbr | denotes | CR |
| SS1_25054392_17_0 | 2268-2278 | expanded | denotes | odds ratio |
| SS2_25054392_17_0 | 2280-2282 | abbr | denotes | OR |
| SS1_25054392_17_1 | 2295-2314 | expanded | denotes | confidence interval |
| SS2_25054392_17_1 | 2316-2318 | abbr | denotes | CI |
| SS1_25054392_20_0 | 2640-2673 | expanded | denotes | treatment-emergent adverse events |
| SS2_25054392_20_0 | 2675-2680 | abbr | denotes | TEAEs |
| AE1_25054392_2_0 | SS1_25054392_2_0 | SS2_25054392_2_0 | abbreviatedTo | prolonged release,PR |
| AE1_25054392_4_0 | SS1_25054392_4_0 | SS2_25054392_4_0 | abbreviatedTo | controlled release,CR |
| AE1_25054392_17_0 | SS1_25054392_17_0 | SS2_25054392_17_0 | abbreviatedTo | odds ratio,OR |
| AE1_25054392_17_1 | SS1_25054392_17_1 | SS2_25054392_17_1 | abbreviatedTo | confidence interval,CI |
| AE1_25054392_20_0 | SS1_25054392_20_0 | SS2_25054392_20_0 | abbreviatedTo | treatment-emergent adverse events,TEAEs |
Linmchun_800_3
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-28 | CI | denotes | Tapentadol prolonged release |
| T10 | 2396-2409 | CI | denotes | tapentadol PR |
| T11 | 2708-2721 | CI | denotes | tapentadol PR |
| T12 | 2822-2835 | CI | denotes | tapentadol PR |
| T13 | 2969-2982 | CI | denotes | tapentadol PR |
| T14 | 3060-3073 | CI | denotes | tapentadol PR |
| T15 | 3205-3218 | CI | denotes | tapentadol PR |
| T19 | 904-920 | CI | denotes | Morphine sulfate |
| T2 | 112-140 | CI | denotes | Tapentadol prolonged release |
| T20 | 871-873 | CI | denotes | CR |
| T21 | 1299-1310 | CI | denotes | morphine CR |
| T22 | 1253-1264 | CI | denotes | morphine CR |
| T23 | 2448-2459 | CI | denotes | morphine CR |
| T24 | 2747-2758 | CI | denotes | morphine CR |
| T25 | 2846-2857 | CI | denotes | morphine CR |
| T26 | 2988-2999 | CI | denotes | morphine CR |
| T27 | 3078-3089 | CI | denotes | morphine CR |
| T28 | 3222-3233 | CI | denotes | morphine CR |
| T3 | 315-328 | CI | denotes | tapentadol PR |
| T33 | 62-98 | DP | denotes | chronic malignant tumor-related pain |
| T34 | 220-256 | DP | denotes | diabetic peripheral neuropathic pain |
| T35 | 420-456 | DP | denotes | chronic malignant tumor-related pain |
| T36 | 3413-3449 | DP | denotes | chronic malignant tumor-related pain |
| T37 | 182-204 | DP | denotes | chronic osteoarthritis |
| T38 | 384-386 | CI | denotes | CR |
| T39 | 3566-3568 | CI | denotes | CR |
| T4 | 820-833 | CI | denotes | tapentadol PR |
| T40 | 355-382 | CI | denotes | morphine controlled release |
| T41 | 3315-3328 | CI | denotes | tapentadol PR |
| T42 | 3495-3508 | CI | denotes | tapentadol PR |
| T43 | 3549-3565 | CI | denotes | morphine sulfate |
| T5 | 1335-1348 | CI | denotes | tapentadol PR |
| T6 | 1377-1390 | CI | denotes | tapentadol PR |
| T7 | 854-870 | CI | denotes | morphine sulfate |
| T8 | 142-144 | CI | denotes | PR |
| T9 | 2220-2233 | CI | denotes | tapentadol PR |
luoyt2021_800_3
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 112-140 | CI | denotes | Tapentadol prolonged release |
| T10 | 2396-2409 | CI | denotes | tapentadol PR |
| T11 | 2220-2233 | CI | denotes | tapentadol PR |
| T12 | 1335-1348 | CI | denotes | tapentadol PR |
| T14 | 820-833 | CI | denotes | tapentadol PR |
| T15 | 315-328 | CI | denotes | tapentadol PR |
| T16 | 62-98 | DP | denotes | chronic malignant tumor-related pain |
| T17 | 182-204 | DP | denotes | chronic osteoarthritis |
| T18 | 220-256 | DP | denotes | diabetic peripheral neuropathic pain |
| T19 | 420-456 | DP | denotes | chronic malignant tumor-related pain |
| T2 | 142-144 | CI | denotes | PR |
| T20 | 3413-3449 | DP | denotes | chronic malignant tumor-related pain |
| T21 | 3222-3233 | CI | denotes | morphine CR |
| T22 | 3078-3089 | CI | denotes | morphine CR |
| T23 | 2988-2999 | CI | denotes | morphine CR |
| T24 | 2747-2758 | CI | denotes | morphine CR |
| T25 | 2846-2857 | CI | denotes | morphine CR |
| T26 | 2448-2459 | CI | denotes | morphine CR |
| T27 | 1299-1310 | CI | denotes | morphine CR |
| T28 | 1253-1264 | CI | denotes | morphine CR |
| T29 | 0-28 | CI | denotes | Tapentadol prolonged release |
| T31 | 3549-3565 | CI | denotes | morphine sulfate |
| T32 | 3566-3568 | CI | denotes | CR |
| T33 | 3205-3218 | CI | denotes | tapentadol PR |
| T34 | 3495-3508 | CI | denotes | tapentadol PR |
| T35 | 1377-1390 | CI | denotes | tapentadol PR |
| T36 | 871-873 | CI | denotes | CR |
| T37 | 384-386 | CI | denotes | CR |
| T38 | 854-870 | CI | denotes | morphine sulfate |
| T39 | 904-920 | CI | denotes | Morphine sulfate |
| T40 | 355-382 | CI | denotes | morphine controlled release |
| T41 | 3315-3328 | CI | denotes | tapentadol PR |
| T6 | 3060-3073 | CI | denotes | tapentadol PR |
| T7 | 2969-2982 | CI | denotes | tapentadol PR |
| T8 | 2822-2835 | CI | denotes | tapentadol PR |
| T9 | 2708-2721 | CI | denotes | tapentadol PR |